Literature DB >> 16740268

LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes.

Susan J Murdoch1, Andrew P Boright, Andrew D Paterson, Bernard Zinman, Michael Steffes, Patricia Cleary, Karen Edwards, Santica S Marcovina, Jonathan Q Purnell, John D Brunzell.   

Abstract

Apo E plays an important role in chylomicron and VLDL remnant processing, uptake or conversion to LDL. The type of lipoprotein that isolates in the LDL density of E2/2 subjects was investigated and the effect of the apo E isoforms on LDL mass was determined in all genotypes in a large group of Type 1 diabetics. Analysis of the LDL composition of E2/2 homozygotes (n=6) compared to subjects with the common E3/3 isoform (n=6) demonstrated an enrichment in apo E, unesterified cholesterol, phospholipid and triglyceride relative to apo B in E2/2 subjects, more typical of a dense IDL remnant than of LDL. Although diabetics were studied, these findings are considered to reflect those of the general population. Comparison of the lipoprotein distribution of homozygous and heterozygous subjects revealed that, as genotype changed from E4/4 (n=22) to E3/4 (n=262), E3/3 (n=710)=E2/4 (n=30), E2/3 (n=151), E2/2 (n=6), LDL cholesterol decreased significantly in a stepwise manner. The decrease was not in a specific subgroup of LDL. In conclusion, for E2/2 subjects, lipoproteins isolated in the LDL density range appear to be composed mainly of dense IDL remnants and some Lp(a). The apo E isoform also has a significant effect on LDL concentration in both homozygotes and heterozygotes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740268      PMCID: PMC2628303          DOI: 10.1016/j.atherosclerosis.2006.04.023

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  35 in total

1.  Effect of lipid transfer proteins on lipoprotein lipase induced transformation of VLDL and HDL.

Authors:  S J Murdoch; W C Breckenridge
Journal:  Biochim Biophys Acta       Date:  1996-10-18

2.  Apolipoprotein E genotype is a determinant of low-density lipoprotein cholesterol and of its response to a low-cholesterol diet in Type 1 diabetic patients with elevated urinary albumin excretion.

Authors:  E E Blaauwwiekel; B J Beusekamp; W J Sluiter; K Hoogenberg; R P Dullaart
Journal:  Diabet Med       Date:  1998-12       Impact factor: 4.359

3.  Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans.

Authors:  S M Marcovina; J J Albers; E Wijsman; Z Zhang; N H Chapman; H Kennedy
Journal:  J Lipid Res       Date:  1996-12       Impact factor: 5.922

4.  The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group.

Authors: 
Journal:  Diabetes       Date:  1986-05       Impact factor: 9.461

5.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

6.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study.

Authors:  E J Schaefer; S Lamon-Fava; S Johnson; J M Ordovas; M M Schaefer; W P Castelli; P W Wilson
Journal:  Arterioscler Thromb       Date:  1994-07

8.  Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a).

Authors:  S M Marcovina; J J Albers; B Gabel; M L Koschinsky; V P Gaur
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

9.  Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse.

Authors:  L A Woollett; Y Osono; J Herz; J M Dietschy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

10.  Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.

Authors:  J Q Purnell; J E Hokanson; S M Marcovina; M W Steffes; P A Cleary; J D Brunzell
Journal:  JAMA       Date:  1998-07-08       Impact factor: 157.335

View more
  7 in total

1.  Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort.

Authors:  A M Jacobson; C M Ryan; P A Cleary; B H Waberski; K Weinger; G Musen; W Dahms
Journal:  Diabetologia       Date:  2010-08-29       Impact factor: 10.122

2.  The effect of APOE genotype on brain levels of oxysterols in young and old human APOE epsilon2, epsilon3 and epsilon4 knock-in mice.

Authors:  A M Jenner; W L F Lim; M P E Ng; M R Wenk; G Shui; M J Sharman; S E Gandy; R N Martins
Journal:  Neuroscience       Date:  2010-04-21       Impact factor: 3.590

3.  Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects.

Authors:  Esther M M Ooi; Edward D Janus; Susan J Grant; Lucia M T Sinclair; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2010-04-22       Impact factor: 5.922

4.  The associations of apolipoprotein E and angiotensin-converting enzyme polymorphisms and cognitive function in Type 1 diabetes based on an 18-year follow-up of the DCCT cohort.

Authors:  A M Jacobson; A D Paterson; C M Ryan; P A Cleary; B H Waberski; K Weinger; G Musen; W Dahms; M Bayless; N Silvers; J Harth; A P Boright
Journal:  Diabet Med       Date:  2010-01       Impact factor: 4.359

5.  Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein.

Authors:  Ioannis Papaioannou; J Paul Simons; James S Owen
Journal:  Cardiol Res Pract       Date:  2012-05-07       Impact factor: 1.866

Review 6.  Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.

Authors:  Alan Chait; Henry N Ginsberg; Tomas Vaisar; Jay W Heinecke; Ira J Goldberg; Karin E Bornfeldt
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

7.  Alzheimer's disease and type 2 diabetes: the association study of polymorphisms in tumor necrosis factor-alpha and apolipoprotein E genes.

Authors:  Maja Mustapic; Marijana Popovic Hadzija; Mladen Pavlovic; Pajica Pavkovic; Paola Presecki; Danijela Mrazovac; Ninoslav Mimica; Marina Korolija; Nela Pivac; Dorotea Muck-Seler
Journal:  Metab Brain Dis       Date:  2012-05-14       Impact factor: 3.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.